Annexon Outlines 2024 Priorities with Late-Stage Clinical

ANX005 Phase 3 Pivotal Data in Guillain-Barré Syndrome (GBS) On Track for First Half of 2024;Potential to be First Approved Treatment for GBS Patients in...

Related Keywords

Brisbane ,Queensland ,Australia ,San Francisco ,California ,United States ,Monique Allaire ,Sheryl Seapy ,Strategic Communications ,Annexon Inc ,Securities Exchange ,Nasdaq ,Global Registration Program ,Global Pivotal Program In Geographic Atrophy ,First Half ,First Approved Treatment ,Pivotal Program ,Geographic Atrophy ,Pivotal Trial Using Vision Preservation ,Primary Outcome Measure ,Proof Of Concept Study ,Kind Oral Small Molecule Inhibitor ,Classical Pathway ,Financing Extends Operating Runway ,Second Quarter ,Douglas Love ,Report Pivotal Data ,Initiate Global Registration Program ,Vision Preservation ,Autoimmune Disease ,Proof Of Concept Clinical Trial ,Healthcare Conference ,Securities Act ,Securities Exchange Act ,Annual Report ,Quarterly Reports ,Private Securities Litigation Reform Act ,Nasdaq Annx ,Annexon Biosciences ,